NCT04445935View on ClinicalTrials.gov

Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial

PHASE4UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 28, 2020

Primary Completion Date

September 28, 2020

Study Completion Date

March 28, 2021

Conditions
Anticoagulation in COVID-19 ARDS
Interventions
DRUG

Bivalirudin Injection

The patients will receive iv Bivalirudin according to the institutional HIT protocol.

DRUG

Standard treatment

This group will receive standard anticoagulation with LMWH/UFH

Trial Locations (1)

Unknown

RECRUITING

Hamad Medical Corporation, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY